Innovative efforts to inhibit KRAS-dependent tumor growth by extinguishing KRAS downstream signaling pathways have led to the important observation that suppressing the mitogen-activated protein kinase (MAPK) cascade RAF/MEK/ERK is necessary but insufficient7. This evidence concerns the gene KRAS and neoplasm.